RAND Corporation, 1776 Main St, Santa Monica, CA, 90407-2138, USA.
University Pittsburgh, Pittsburgh, PA, USA.
Addict Sci Clin Pract. 2022 Jul 28;17(1):39. doi: 10.1186/s13722-022-00320-7.
People with opioid use disorder experience high burden of disease from medical comorbidities and are increasingly hospitalized with medical complications. Medications for opioid use disorder are an effective, life-saving treatment, but patients with an opioid use disorder admitted to the hospital seldom initiate medication for their disorder while in the hospital, nor are they linked with outpatient treatment after discharge. The inpatient stay, when patients may be more receptive to improving their health and reducing substance use, offers an opportunity to discuss opioid use disorder and facilitate medication initiation and linkage to treatment after discharge. An addiction-focus consultative team that uses evidence-based tools and resources could address barriers, such as the need for the primary medical team to focus on the primary health problem and lack of time and expertise, that prevent primary medical teams from addressing substance use.
This study is a pragmatic randomized controlled trial that will evaluate whether a consultative team, called the Substance Use Treatment and Recovery Team (START), increases initiation of any US Food and Drug Administration approved medication for opioid use disorder (buprenorphine, methadone, naltrexone) during the hospital stay and increases linkage to treatment after discharge compared to patients receiving usual care. The study is being conducted at three geographically distinct academic hospitals. Patients are randomly assigned within each hospital to receive the START intervention or usual care. Primary study outcomes are initiation of medication for opioid use disorder in the hospital and linkage to medication or other opioid use disorder treatment after discharge. Outcomes are assessed through participant interviews at baseline and 1 month after discharge and data from hospital and outpatient medical records.
The START intervention offers a compelling model to improve care for hospitalized patients with opioid use disorder. The study could also advance translational science by identifying an effective and generalizable approach to treating not only opioid use disorder, but also other substance use disorders and behavioral health conditions.
Clinicaltrials.gov: NCT05086796, Registered on 10/21/2021. https://www.
gov/ct2/results?recrs=ab&cond=&term=NCT05086796&cntry=&state=&city=&dist = .
患有阿片类药物使用障碍的人患有多种合并症,疾病负担沉重,并且越来越多地因医疗并发症住院。阿片类药物使用障碍药物是一种有效且救命的治疗方法,但因阿片类药物使用障碍而住院的患者在住院期间很少开始治疗他们的疾病,也没有在出院后与门诊治疗联系起来。住院期间,患者可能更愿意改善健康状况并减少物质使用,这为讨论阿片类药物使用障碍并促进药物治疗的开始和出院后的联系提供了机会。一个使用循证工具和资源的以成瘾为重点的咨询团队可以解决一些障碍,例如主要医疗团队需要专注于主要健康问题、缺乏时间和专业知识,这些障碍阻止了主要医疗团队解决物质使用问题。
这是一项实用的随机对照试验,旨在评估一个名为“物质使用治疗和康复团队”(START)的咨询团队是否会增加任何美国食品和药物管理局批准的阿片类药物使用障碍治疗药物(丁丙诺啡、美沙酮、纳曲酮)的使用在住院期间的开始,并与接受常规护理的患者相比,增加出院后的治疗联系。该研究在三个地理位置不同的学术医院进行。在每个医院内,患者被随机分配接受 START 干预或常规护理。主要研究结果是在医院内开始使用阿片类药物使用障碍药物治疗以及出院后与药物或其他阿片类药物使用障碍治疗的联系。通过参与者在基线和出院后 1 个月的访谈以及医院和门诊病历中的数据来评估结果。
START 干预提供了一种改善住院阿片类药物使用障碍患者护理的有吸引力的模式。该研究还可以通过确定一种有效且可推广的方法来治疗不仅是阿片类药物使用障碍,而且是其他物质使用障碍和行为健康状况,从而推进转化科学。
ClinicalTrials.gov:NCT05086796,注册于 2021 年 10 月 21 日。https://www.clinicaltrials.gov/ct2/results?recrs=ab&cond=&term=NCT05086796&cntry=&state=&city=&dist=。